CarnoSyn® Brands Showcasing TriBsyn™ at the 46th ESPEN Congress On Clinical Nutrition & Metabolism
Natural Alternatives International (NAI) and CarnoSyn® Brands will showcase TriBsyn™, a patent-pending formula, at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy from September 7-10, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Natural Alternatives International (NAI) and CarnoSyn® Brands will showcase TriBsyn™, a patent-pending formula, at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy from September 7-10, 2024. TriBsyn™ utilizes proprietary technology to increase beta-alanine bioavailability and absorption while eliminating paresthesia associated with high doses of beta-alanine.
The team will be at stand #16 to discuss the latest clinical evidence of TriBsyn™, which offers opportunities for various consumer groups, including older adults and vegans. Aaron Starr, VP of CarnoSyn® Brands, highlighted the product's potential in addressing the growing demand for healthy aging and wellness solutions. The team will also attend the 20th European Geriatric Medicine Society Congress in Valencia, Spain on September 18-20.
Positive
- Introduction of TriBsyn™, a new patent-pending formula with increased beta-alanine bioavailability
- Expansion into untapped consumer markets, including older adults and vegans
- Potential applications in dietary supplements, fortified foods, and medical foods
Negative
- None.
Details
News Market Reaction – NAII
The recorded move for NAII in the trading session of this news was +4.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands will exhibit at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy on September 7-10, 2024. ESPEN 2024 offers a unique platform for companies to present and educate on innovative science in clinical nutrition and metabolism, fostering collaboration with physicians, dietitians, pharmacists, nutritionists, scientists, and nurses.
The NAI and CarnoSyn® Brands team will be available at stand #16 to discuss the latest clinical evidence of TriBsyn™, a patent-pending formula that utilizes proprietary technology to increase beta-alanine bioavailability and absorption, while effectively eliminating the common paresthesia sensation associated with efficacious dosages of beta-alanine. TriBsyn™ provides new opportunity to reach untapped consumers from older adults to vegans and anyone focused on wellness. Congress attendees are invited to visit the stand to learn more about this new product innovation.
Aaron Starr, Vice President, CarnoSyn® Brands stated, “We are excited to exhibit TriBsyn™ at this year’s ESPEN Congress on Clinical Nutrition and Metabolism and to share details behind the clinically proven formula. There is an evolving need and growing demand for healthy aging and wellness solutions, and this proprietary carnosine booster is a game changer for dietary supplement categories, as well as for fortified and medical foods, seeking benefit focus on muscle vitality, cognitive performance, and anti-aging support.”
Following ESPEN, the team will attend the 20th European Geriatric Medicine Society (EuGMS) Congress in Valencia, Spain on September 18-20.
Find out more about TriBsyn™ by visiting ESPEN stand #16 or www.tribsyn.com.
About CarnoSyn® Brands:
CarnoSyn® Brands feature three clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder. In 2019, CarnoSyn® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status. SR CarnoSyn®, an advanced delivery form of CarnoSyn®, received GRAS affirmation in 2017. The new “paresthesia-free” TriBsyn™ powder allows NAI to broaden their product offerings within the dietary supplement category, including medical and other fortified food products. To learn more about SR CarnoSyn® in active nutrition and wellness, visit www.srcarnosyn.com. For more information about the latest innovation, TriBsyn™, visit www.tribsyn.com.
About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please visit www.nai-online.com.
Contact:
Renee Michaelson
Director of Global Marketing
NAI/CarnoSyn® Brands
(760) 736-7700
info@nai-online.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.